Accelerating Development of GLP-1 & GLP-2 Therapeutics with Validated Bioassays
Glucagon-like peptides, GLP-1 & GLP-2, are well-researched, metabolically significant peptide hormones secreted from the L-cells of the small intestine in response to... Read More
Evaluate GLP-1R Targeted Therapeutics Using First-to-Market Semaglutide Qualified GLP-1R Bioassay
Glucagon-Like Peptide-1 (GLP-1), a member of the glucagon-secretin peptide family, is secreted from L-cells of the small intestine and binds to GLP-1... Read More
SPRINTer Platform: Detection of Endogenous Protein Turnover by Targeted Degraders
A novel and growing modality in drug discovery has been the application of Targeted Protein Degradation (TPD). TPD involves the use of... Read More
ACCELERATING CYTOKINE DRUG DISCOVERY AND QC LOT RELEASE TESTING WITH QUALIFIED, FUNCTIONAL CELL-BASED ASSAYS
Cytokines and their receptors have emerged as major drug targets for inflammatory and autoimmune diseases, allergies, and, more recently, in cancer immunotherapies... Read More
EMPLOYING KILR CYTOTOXICITY READY-TO-USE BIOASSAYS FROM SCREENING TO LOT-RELEASE APPLICATIONS
Webinar Highlights and Q&A Webinar: Cytotoxicity Bioassays – Measuring Antibody-Mediated Direct Cell Death (watch webinar) Therapeutic antibodies that can elicit different applications... Read More
Unlocking Orphan GPCRs with an Innovative Forward Trafficking Approach
Application of GPCR Pharmacotrafficking & Cell-Based Assays Orphan G Protein-Coupled Receptors (oGPCRs) comprise one-third of the druggable GPCR space1. Despite their pharmacotherapeutic... Read More
USE OF AUTOMATED FUNCTIONAL, CELL-BASED BIOASSAYS
Importance in Drug Discovery & Development for Quality Testing Programs Cell-based assays have emerged as crucial tools for basic and applied research.... Read More